Abstract
Aim: Ceritinib was evaluated within a compassionate use program of Italian patients. Patients & methods: 70 patients with anaplastic lymphoma kinase-positive crizotinib-refractory advanced non-small-cell lung cancer received ceritinib. Results: Overall response was 40.6%, median progression-free survival was 8.2 months and median survival was 15.5 months. Dose reduction due to treatment-related adverse events occurred in 50.8% of patients starting at 750 mg/day. No significantly different progression-free survival was observed between patients who underwent any time dose reduction (n = 38) versus those who remained on the recommended dose of 750 mg/day (n = 32; p = 0.07). Conclusion: The efficacy of ceritinib compassionate use program resembled that of clinical trials. Dose reductions and adjustments did not appear to negatively affect clinical outcome.
Original language | English |
---|---|
Pages (from-to) | 353-361 |
Number of pages | 9 |
Journal | Future Oncology |
Volume | 14 |
Issue number | 4 |
DOIs | |
Publication status | Published - Feb 1 2018 |
Keywords
- ALK
- ceritinib
- non-small-cell lung cancer
ASJC Scopus subject areas
- Oncology
- Cancer Research